[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648566":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":27,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Ketamine\u002FEsketamine",null,"Participants with a major depressive episode and moderate to severe suicidal thoughts or behaviors who are scheduled to receive intravenous ketamine or intranasal esketamine as part of routine clinical care. Treatment is determined by the clinical care team and is not assigned by the study. Participants complete clinical, behavioral, MRI, and EEG assessments before and after treatment.",{"label":13,"type":10,"description":14,"interventionNames":10},"Electroconvulsive Therapy (ECT)","Participants with a major depressive episode and moderate to severe suicidal thoughts or behaviors who are scheduled to receive an acute course of electroconvulsive therapy (ECT) as part of routine clinical care. Treatment is determined by the clinical care team and is not assigned by the study. Participants complete clinical, behavioral, MRI, and EEG assessments before and after treatment.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Joan Camprodon, MD, PhD, MPH","CONTACT","617-726-5340","JCAMPRODON@mgh.harvard.edu",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Joan A Camprodon, MD MPH PhD","Chief, Division of Neuropsychiatry and Interventional Psychiatry","100648566","biomarker-discovery-for-suicide-precision-circuit-therapeutics-100648566",false,"NCT07723066","Biomarker Discovery for Suicide Precision Circuit Therapeutics","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Diagnosis of a major depressive episode associated with Major Depressive Disorder or Bipolar Disorder\n* Presence of moderate to severe suicidal thoughts or behaviors, as determined by the Beck Scale for Suicide Ideation (BSSI)\n* Scheduled to receive an acute treatment course of electroconvulsive therapy (ECT), intravenous ketamine, or intranasal esketamine as part of routine clinical care\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Neurological disorders, particularly conditions associated with known structural brain lesions\n* Inability to meet MRI safety requirements\n* Current alcohol dependence\n* Active symptoms of non-alcohol psychoactive substance withdrawal","ALL","18 Years","65 Years",{"count":35,"type":36},60,"ESTIMATED","OBSERVATIONAL","This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine\u002Fesketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.",[40,41],"Suicidal Thoughts and Behaviors","Major Depressive Episode (MDE)","NOT_YET_RECRUITING","2026-07-20",{"date":45,"type":46},"2026-07-23","ACTUAL",{"date":48,"type":36},"2026-07",{"date":50,"type":36},"2030-08-31",{"name":5,"class":6}]